Rare Genetic Variant Raises Lung Cancer Odds 25-Fold in Never-Smokers

Investigators mined exome and health records from over 1 million 23andMe participants to isolate the variant, then validated carrier status against lung cancer diagnoses in never-smokers versus controls. The analysis adjusted for age, sex, and ancestry, revealing the 25-fold odds ratio while noting the variant explains only a small fraction of never-smoker cases. Regional enrichment in Appalachia suggests founder effects or interaction with local exposures such as radon.

Prior observational cohorts in NEJM and JAMA Oncology had documented rising never-smoker lung cancer incidence without clear drivers; this work supplies a concrete germline mechanism that complements somatic EGFR/ALK findings. It also flags that standard smoking-based screening criteria will miss genetically susceptible individuals, prompting calls for ancestry-informed risk models.

Next steps include targeted sequencing in independent biobanks and prospective screening trials in high-prevalence regions to measure absolute risk and test whether earlier imaging alters outcomes.